FDA allows Alnylam to restart hemophilia treatment trials

(Reuters) - The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical tests on a drug to treat patients with a rare bleeding disorder, the company said on Friday.